Resultados de la búsqueda 121-130 of 3593 for charcoal-activated-oral-route

  1. Resultados de la búsqueda - Medicamentos y suplementos - Mayo Clinic

    Stiripentol (Oral Route) Description and Brand Names - Mayo Clinic. Skip to content Care at Mayo Clinic Patient-Centered Care About Mayo Clinic Request ...

  2. Salud del adulto - Mayo Clinic

    De Mayo Clinic a tu buzón. Inscríbete gratis y mantente al día en cuanto a avances en las investigaciones, consejos sobre salud, temas médicos de actualidad ...

  3. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  4. Hematología - Ensayos clínicos - Mayo Clinic

    The drugs in the FOLFOX regimen are all FDA (Food and Drug Administration) approved and have been used routinely to treat patients with advanced colorectal ...

  5. Cirugía - Ensayos clínicos - Mayo Clinic

    Rochester, Minn. The purposes of this study are to determine whether maternal T cells are activated and expand after in utero intervention, and to determine ...

  6. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    This is a multi-center, open-label trial of orally administered CA-4948 monotherapy in adult patients with Relapsed or Refractory NHL. ... administration of MV-s- ...

  7. Hematología - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...

  9. Hematología - Ensayos clínicos - Mayo Clinic

    Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive ...

  10. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Patients randomized to GDC-0199+R will be given GDC-0199 daily (oral, target dose 400 mg) and will receive 6 cycles of rituximab infused intravenously (IV) ...